Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis

mRECIST for HCC: Performance and novel refinements

(2020) Josep M. Llovet et al.   JOURNAL OF HEPATOLOGY

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics

(2020) Sadal Refae et al.   Scientific Reports

The future of cancer immunotherapy: microenvironment-targeting combinations

(2020) Yonina R. Murciano-Goroff et al.   CELL RESEARCH

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

(2020) Masatoshi Kudo   Cancers

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

(2020) Richard S. Finn et al.   JOURNAL OF CLINICAL ONCOLOGY

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab

(2020) Daisuke Nishikawa et al.   CANCER SCIENCE

Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma

(2020) Chang Gon Kim et al.   JOURNAL OF HEPATOLOGY

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

(2020) Giulia Orsi et al.   Targeted Oncology

Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients

(2020) Seung-Myoung Son et al.   Scientific Reports

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

(2020) Thomas Yau et al.   JAMA Oncology

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

(2020) Petros Fessas et al.   Journal for ImmunoTherapy of Cancer

Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma

(2020) Adi Kartolo et al.   Immunotherapy

Novel patterns of response under immunotherapy

(2019) E Borcoman et al.   ANNALS OF ONCOLOGY

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

(2019) Andrew X Zhu et al.   LANCET ONCOLOGY

Hepatocellular Carcinoma

(2019) Augusto Villanueva   NEW ENGLAND JOURNAL OF MEDICINE

Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

(2019) Li-Chun Lu et al.   Liver Cancer

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response

(2019) Bridget P. Keenan et al.   Journal for ImmunoTherapy of Cancer

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab

(2018) Richard W. Joseph et al.   CLINICAL CANCER RESEARCH

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

(2018) M. Tazdait et al.   EUROPEAN JOURNAL OF CANCER

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

(2018) Masatoshi Kudo et al.   LANCET

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

(2018) Andrew X Zhu et al.   LANCET ONCOLOGY

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

(2018) Ghassan K. Abou-Alfa et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional Approach

(2018) Daniëlle Krijgsman et al.   Frontiers in Immunology

Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment

(2018) Li-Chun Lu et al.   Liver Cancer

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Opposing roles of eosinophils in cancer

(2018) Sonja C. S. Simon et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab

(2017) Tomoko Funazo et al.   Journal of Thoracic Oncology

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

(2017) Jordi Bruix et al.   LANCET

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

(2017) Anthony B El-Khoueiry et al.   LANCET

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

(2017) Paul C. Tumeh et al.   Cancer Immunology Research

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients

(2016) Leila Khoja et al.   BRITISH JOURNAL OF CANCER

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib

(2016) Shao-Lai Zhou et al.   GASTROENTEROLOGY

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

(2016) Andrea Casadei Gardini et al.   Oncotarget

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

(2016) E. Liniker et al.   OncoImmunology

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

(2016) Viktor H. Koelzer et al.   Journal for ImmunoTherapy of Cancer

Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells

(2015) Philipp Müller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

(2015) Andrew X Zhu et al.   LANCET ONCOLOGY

Immunological landscape and immunotherapy of hepatocellular carcinoma

(2015) Jesús Prieto et al.   Nature Reviews Gastroenterology & Hepatology

Patrolling monocytes control tumor metastasis to the lung

(2015) R. N. Hanna et al.   SCIENCE

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens

(2015) Marina K Baine et al.   Oncotarget

Identification of a FOXP3+CD3+CD56+ population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma

(2015) Xiaofeng Li et al.   Scientific Reports

Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous

(2015) Ratnadeep Mukherjee et al.   Scientific Reports

Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF- 1

(2014) H. Li et al.   JOURNAL OF IMMUNOLOGY

Cancer heterogeneity: implications for targeted therapeutics

(2013) R Fisher et al.   BRITISH JOURNAL OF CANCER

Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

(2013) Fumitaka Arihara et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma

(2013) Tobias Flecken et al.   HEPATOLOGY

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

(2012) Hang Li et al.   HEPATOLOGY

T cell exhaustion

(2011) E John Wherry   NATURE IMMUNOLOGY

Immune tolerance: What is unique about the liver

(2009) Gisa Tiegs et al.   JOURNAL OF AUTOIMMUNITY

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

(2008) Bastian Hoechst et al.   GASTROENTEROLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE